A PHASE I STUDY OF THE NOVEL RIBONUCLEOTIDE REDUCTASE INHIBITOR 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE (3-AP, TRIAPINE®) IN COMBINATION WITH THE NUCLEOSIDE ANALOG FLUDARABINE FOR PATIENTS WITH REFRACTORY ACUTE LEUKEMIAS AND AGGRESSIVE MYELOPROLIFERATIVE DISORDERS

Triapine® is a potent ribonucleotide reductase (RR) inhibitor that depletes intracellular deoxyribonculeotide pools, especially dATP. We designed a Phase I trial of Triapine followed by the adenosine analog fludarabine in adults with refractory acute leukemias and aggressive myeloproliferative disor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Karp, Judith E., Giles, Francis J., Gojo, Ivana, Morris, Lawrence, Greer, Jacqueline, Johnson, Bonny, Thein, Mya, Sznol, Mario, Low, Jennifer
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2726775/
https://ncbi.nlm.nih.gov/pubmed/17640728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2007.05.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados